Two low molecular weight (LMW) apoproteins were isolated from human pulmonary surfactant. SDS polyacrylamide gel analysis showed one protein (SP 18) to have an apparent molecular weight of 18,000 when unreduced and 9,000 D after reduction. The second protein (SP 9) migrated at -9,000 D in the presence or absence of reducing agents. Both proteins contain a high number of hydrophobic amino acids. The NH2-terminal sequence of SP 18 was determined to be: NH2-phe-proile-pro-leu-pro-tyr-. A cDNA clone isolated from a human adult lung cDNA library contained a long open reading frame encoding at an internal position the human SP 18 amino-terminal sequence.
Introduction
Pulmonary surfactant, which lines the alveolar epithelium of mature mammalian lungs, has been shown to be a lipoprotein complex capable of reducing surface tension at the air-liquid interface (1, 2) . The apoproteins present in this complex have been the subject of many studies over the past few years which have helped to elucidate the physiologic role they play in surfactant activity. While initial interest seemed focused primarily on a 35,000-D major glycoprotein (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , more recent studies have described hydrophobic 5,000-18,000-D apoproteins (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) Revak. Receivedfor publication 25 June 1987 and in revisedform 28 September 1987. expression of surfactant surface tension reduction activity.
These low molecular weight (LMW)' apoproteins, one of which has been described as a "proteolipid" (21) , can be found in several organic surfactant lipid extracts being tested clinically (Tokyo Tanabe's "surfactant TA," calf lung surfactant extract) that have also been shown not to contain the 35,000-D apoprotein (20, 23, 25) . That the 35,000-D and the LMW apoproteins of surfactant are distinct has been shown immunologically (22) (23) (24) (25) (26) , and different amino acid compositions (4, 8, 14, 16, 17, 19, 21, 23, 25) have been reported. In the canine system, two unique amino acid sequences have been derived from cDNA clones (27, 28) . While it is apparent that the LMW apoproteins represent a group of proteins clearly distinguishable from the 35 ,000-D surfactant apoprotein, it is not clear as to whether this group is comprised of one or more apoproteins and what differences exist in their characteristics and functions if there are multiple proteins.
We have previously reported the isolation of the 35,000-D protein from human amniotic fluid surfactant and studied its ability when added to phospholipids to lower the surface tension ofa pulsating bubble and to increase lung compliance and alveolar expansion when instilled into fetal rabbits (17) . In the current study we have isolated two LMW apoproteins from human amniotic fluid surfactant, partially characterized them, and used the same pulsating bubble and fetal rabbit models to show that each can be recombined with synthetic phospholipids (PL) to yield a functionally active reconstituted surfactant. Furthermore, a cDNA clone corresponding to the larger apoprotein has been isolated and its nucleotide sequence determined. We will refer to these two distinct LMW apoproteins as surfactant protein (SP) 18 and SP 9, with the number following SP indicating the molecular weight (in kilodaltons) of the protein as it appears in unreduced SDS-PAGE.
Methods
Purification ofLMW apoproteins. Human pulmonary surfactant was isolated from full-term amniotic fluid and applied to a column of DEAE-Sephacel A-50 (Pharmacia Fine Chemicals, Uppsala, Sweden) using 4 ml packed volume per 200 mg surfactant, in a Tris-EDTA buffer containing 1% n-octyl-beta-D-glucopyranoside as previously described (17, 29) . This particular column and conditions were used to isolate the 35,000-D apoprotein (for use in other studies) without exposing it to potentially denaturing organic solvents. The void volume, containing the lipids and proteins that did not bind to the column under these conditions, was pooled and extracted with an equal vol-ume of 2:1 chloroform/methanol. After centrifugation to separate the phases, the upper phase (water plus methanol) was reextracted with one-half volume chloroform. After centrifugation, the resultant lower organic phase was added to the initial lower phase and evaporated to dryness under a stream of nitrogen. This extract, which contained 100-180 mg PL, LMW apoproteins, and octylglucopyranoside, was redissolved in 2.5 ml chloroform/methanol (2:1). Following the method of Takahashi and Fujiwara (21), which we found to afford a good separation of octylglucopyranside from the LMW proteins and PL, a glass column 2.5 cm in diameter was packed at 40 to a height of 38 cm with Sephadex LH-20 (Pharmacia Fine Chemicals) in 2:1 chloroform/methanol. The sample was loaded and 2-ml fractions collected as chloroform/methanol (2:1) was run through at a flow rate of 8.5 ml/h. PL eluted after 40 ml of buffer had passed through the column. Octylglucopyranoside appeared at the 56-116 ml region. The PL region was pooled, dried under nitrogen, and redissolved in I ml chloroform. A silicic acid column was prepared by packing 9 ml of Bio-Sil HA (Bio-Rad Laboratories, Richmond, CA) in chloroform in a glass column at room temperature. The sample (which contained -50 mg PL) was applied and washed with 11 ml chloroform. A linear gradient of increasing methanol was established using an equal weight of chloroform and methanol (38.8 g, 26.5 ml chloroform and 50 ml methanol). Fractions of 2 ml were collected as the gradient was applied to the column. Fig. 1 (27) , in a volume of 0.5 ml buffer was applied to the top ofthe column, and fractions of0. 5 (30) , using 3 X 7-cm minislab gels. 1% fl-mercaptoethanol was added to samples where indicated as a disulfide reducing agent. After electrophoresis, the gels were fixed overnight in 50% methanol plus 12% acetic acid, washed in water for 2 h, and silver-stained according to the method of Wray et al. (31) .
Octylglucopyranoside assay. An assay for the quantitation of noctyl-beta-D-glucopyranoside, based on the anthrone method of Spiro (32), has been described previously (17) .
Protein determinations. Organic samples containing up to 5 Mig protein were dried in 12 X 75-mm glass tubes under nitrogen. 15 Al of 1% SDS in H20 and 300 Ml BCA Protein Assay Reagent (Pierce Chemical Co., Rockford, IL) were added. Tubes were covered and incubated at 60°C for 30 min. After cooling, the samples were transferred to a 96-well flat-bottom polystyrene microtiter plate and optical density at 550 nm measured. Bovine serum albumin was used as a standard. Note that some phospholipids will react in the BCA protein assay, making protein quantitations inaccurate when lipid is present (i.e., before Bio-Sil HA chromatography). Additionally, once purified, the hydrophobic LMW apoproteins themselves react poorly with the BCA reagents, and all quantitations of the isolated proteins were, therefore, based on amino acid compositions.
PL. Dipalmitoylphosphatidylcholine (DPPC, beta, gamma-dipalmitoyl-L-alpha-lecithin) and L-alpha-phosphatidyl-DL-glycerol ( Fraction Number Surfactant activity assays. In vitro assays of surfactant activity, assessed as its ability to lower the surface tension ofa pulsating bubble, and in vivo assays using fetal rabbits, have both been described in detail previously (17) . Morphometric analyses. Fetal rabbit lungs, inflated to 30 cm H20 and then deflated to 10 cm H20, were submerged in 10O% formalin for 72 h. Parafin sections were oriented from apex to base and 5-Mm sections taken anterior to posterior. After hematoxylin and eosin staining, 10 fields (X 100) were point-counted from apex to base on multiple sections. Standardized morphometric methods (33) were used to determine ratios oflung interstitium to air spaces for each treatment group. Intersections of alveolar perimeters were also determined.
PL phosphorus assays. PL were quantitated according to the method of Bartlett (34 Preparation of double-stranded cDNA was carried out using standard techniques (36, 37) and a library was constructed in lambda NM607 as described (38) . SP 18 clones were identified by screening phage plaques with synthetic oligonucleotide probes (39) that were prepared using an automated synthesizer (Applied Biosystems, Inc.) and purified by HPLC. Initial candidate clones were obtained using probe TG996 (5'CATTGCCTGTGGTATGGCCTGCTC 3'), which was derived from the partial nucleotide sequence of a small human surfactant apoprotein cDNA (40) . Larger clones (up to 1.5 kb) were isolated using probe TGl 103 (5'TCGAGCAGGATGACGGAGTAGCGC 3'), which was based on the 5' sequence of one of the original clones. The nucleotide sequence of the cDNA clones was determined by the chain termination method (41) using Eco RI restriction fragments subcloned in an appropriate M 13 vector.
Results
Characteristics ofthe LMW apoproteins. The LMW apoproteins isolated from human amniotic fluid appeared after silicic acid chromatography, or after the Sephadex LH-20 column chromatography described by Hawgood et al. (27) , as two protein bands in SDS-PAGE under nonreducing conditions. The upper band, having a weight of 18,000 D and therefore termed SP 18, is a dimer, and with the addition of f-mercaptoethanol, reduced to 9,000 D (Fig. 2) . The other LMW apoprotein, which we will call SP 9,2 appears as a diffuse band between 9,000 and 12,000 D in the presence or absence of reducing agents. These two proteins could be separated by chromatography on Sephadex LH-60. The resultant purified proteins are shown in Fig. 2 .
Amino acid compositions were determined for SP 18 and SP 9. Because of the extremely hydrophobic nature of these proteins, HCO hydrolysis was performed at 150'C for 24 h, in addition to the standard 1 10C 24-h hydrolysis, and values for valine, leucine, and isoleucine were calculated from analyses 2. This is probably the same protein as that designated SAP-6 by Whitsett and co-workers (24), SP 5-8 by Hawgood and co-workers (27) , and PSP-6 by Phelps et al. (25) . of the hydrolysates done under the extreme conditions. As shown in Table I , both proteins are extremely hydrophobic, with high levels of valine and leucine.
Amino-terminal sequence analysis of SP 18 yielded the following sequence: NH2-phe-pro-ile-pro-leu-pro-tyr-.
Repeated sequencing of the purified SP 9 protein showed multiple peptides, all rich in leucine and containing at least six consecutive valines. NH2-terminal analysis showed phenylalanine, glycine, and isoleucine, with the relative amounts ofeach varying from preparation to preparation.
Nucleotide sequence analysis ofSP 18 cDNA. The nucleotide sequence of an SP 18 cDNA clone is presented in Fig. 3 . The sequence displays 83% homology with the canine SP 18 cDNA (27) . A sequence within a large open reading frame was identified which matches perfectly with the amino terminus of SP 18, as determined by Edman degradation of the isolated protein (underlined in Fig. 3 ). This suggests that mature SP 18 arises by processing of a larger precursor molecule. In the mature sequence there is a single potential N-glycosylation site (Asn 110), no sites for tyrosine sulfation, and no G-X-Y repeats as found in the 35,000-D apoprotein (15) . The molecular weight of 9,000 obtained by SDS-PAGE of reduced SP 18 is lower than that predicted for the complete sequence with amino terminus NH2-Phe-Pro-Ile-Pro-Leu-Pro-Tyr (19,772 D) , implying further processing in the region ofamino acids 70 to 90. In support of this, the theoretical amino acid composition (column 4, Table I ) of a putative 9,000-D protein comprising residues 1 to 81 compares well with the determined values for purified SP 18. Note, however, that the carboxy terminus is, at this time, unknown. The amino-terminal portion of the protein (residues 1 to 81) is alkaline and more hydrophobic than the COOH-terminal portion (residues 82 to 181): the Kyte-Doolittle index for residues 1 to 81 is 9,100 (pl, 8.6), and is -3,000 (pl, 5.91) for residues 82 to 181 (42) . The amino terminus (residues 1 to 81) is, as in the canine sequence (27) pearing more effective than SP 9 on an equal weight basis. A similar experiment was performed using a mixture of SP 9 and SP 18 for reconstitution. The results were almost identical to the PL plus SP 18 curve presented in Fig. 4 . After compliance measurements, the lungs were inflated to 30 cm H20, deflated back to 10 cm H20, clamped, excised, and fixed in formalin. Thin sections were stained with hematoxylin and eosin and examined microscopically. As shown in Fig. 5 , lungs treated with saline (A) or PL (C) appeared atelectatic, while those from animals that received natural (B) or reconstituted (D) surfac- 
Discussion
This report describes two LMW apoproteins isolated from human amniotic fluid surfactant that can be added to known PL to produce a biologically active surfactant. While we have referred to these proteins in the current study as SP 18 and SP 9, it is apparent from the recent literature that multiple nomenclature and an assortment of reported molecular weights (ranging from 5,000 to 18,000) exist (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . The apparent differences in physical properties may be explained by a variety of factors including species differences, varying purifica- (27) , PSP-6 by Phelps et al. (25) , and the 5-kD proteolipid of Takahashi and Fujiwara (21) . The extremely hydrophobic nature ofthis protein is apparent from its amino acid composition (Table I) and sequence data, which show at least six consecutive valine residues preceded by a leucine-rich region. The presence ofthree amino-terminal residues (phenylalanine, glycine, and isoleucine) in our preparations of SP 9 derived from amniotic fluid surfactant suggests a collection of peptides having an identical sequence but having had one or two residues removed from the amino-terminus. Phelps et al. (25) have recently reported a similar finding with bovine PSP-6 apoprotein. SP 18 appears to be a disulfide-linked dimer of two identical 9,000-D peptides (but different from the 9,000-D peptide of SP 9). A single NH2-terminal sequence, phe-pro-ile-proleu-pro-tyr-, was found. This sequence, with the exception of the NH2-terminal phenylalanine, is identical to that predicted by the canine SP 18 cDNA clone isolated by Hawgood et al. (27) . Amino acid composition (Table I) shows a high number of hydrophobic residues. When unreduced SDS-PAGE were overloaded with SP 18 protein, sequentially less intensely staining bands were seen at 36,000 and 56,000 D, suggesting oligomeric forms of the protein; upon reduction, only a single 9,000-D band was seen (unreported observations).
The nucleotide sequence of an SP 18 cDNA clone predicted that the apoprotein is synthesised as a large precursor that is cleaved to release a 19,722-D protein carrying the NH2-terminal sequence determined by Edman degradation. (Fig. 3) . To obtain the 9,000-D mature polypeptide, a further cleavage near the center of the molecule would be necessary. Interestingly, if cleavage occurs between residues 72 and 98, an uneven number of cysteines would be present in either peptide, one of which may therefore be available for intermolecular bonding.
Comparison of the deduced amino acid sequence of the entire human SP 18 with the canine SP 18 sequence displays an overall homology of 71%, with many of the differences involving conservative changes. There are two additional residues in canine SP 18 (molecular weight, 20,060) but no difference in pl (7.8) . Significantly, all the cysteine and 13 of the 14 proline residues, both of which may be considered as major structural determinants, are conserved and occupy the same position in both proteins. Moreover, the amino-terminal region of the molecule is more conserved (83% homology) between dog and man than the COOH-terminus (69% homology). This is consistent with the first half of the molecule harboring the biological activity.
Both SP 9 and SP 18 apoproteins, isolated as described above, could be shown to have biophysical activity after recombination with PL. The addition of 1% by weight of SP 18 to DPPC/PG resulted in an immediate increase in surface pressure causing surface tensions of < 10 dyn/cm by 15 s. The addition of 1% SP 9 to DPPC/PG was slightly less effective, lowering surface tensions to 16.7, 14.1, and 12.2 dyn/cm at 15 s, 1 and 5 min, respectively. Mixtures of both SP 18 and SP 9 were also effective, but further studies will be required to determine whether the combined effect is additive or synergistic.
In vivo studies of reconstituted surfactant using the fetal rabbit model (43) were performed using mixtures of SP 18 and SP 9 as well as each protein individually. A marked improvement in lung compliance was seen in animals treated with natural surfactant or reconstituted surfactant prepared with SP 18 apoprotein, as compared with those receiving PL alone or saline (Fig. 4) . A moderate improvement was seen when SP 9 was used. Identical studies using a mixture of SP 18 and SP 9 to prepare the reconstituted surfactant showed results very similar to those obtained with SP 18 alone (solid squares , Fig.   4) ; however, the exact ratio of SP 18 and SP 9 in those studies could not be accurately ascertained. Fig. 5 shows representative microscopic alvelor fields, indicating the lack of atelectasis after surfactant instillation.
Suzuki et al. ( 19) have reported a reduction in surface tension (measured on the Wilhelmy balance or in a pulsating bubble), and a fivefold increase in tidal volumes of prematurely delivered rabbits at insufflation pressures of 25 cm H20 when porcine LMW (< 15,000 D) surfactant apoproteins are added to mixtures of DPPC:DPPG) at a weight ratio of 5:80:20 (protein/DPPC/DPPG). Whether one or multiple proteins are present in this system is unclear.
Our previous studies using the 35,000-D apoprotein (17) also showed a moderate reduction in surface tension, similar to that obtained with SP 9 in the current studies. Clearly, further studies must be done using various combinations and concentrations of SP 18, SP 9, and the 35,000-D apoprotein, as well as Ca++ and perhaps various PL to elucidate the interactions between these various components of surfactant and to determine the best conditions for a biologically active recombinant surfactant. Hawgood et al. (27) have shown in the canine system a synergistic, calcium-dependent effect on the stimulation of PL surface film formation by the addition ofthe 35,000-D apoprotein and the LMW apoproteins.
Improvements in lung function as measured by a decrease in mean airway pressure and oxygen requirements is an immediate effect also seen in human preterm infants treated with natural human surfactant (29, (44) (45) (46) or lipid extracts (containing LMW apoproteins) of bovine surfactant (47) (48) (49) (50) (51) (52) . The ability to reproduce the essential components of these surfactants via synthetic means (i.e., genetically engineered proteins combined with synthetic PL) would permit their use in the treatment of not only infant respiratory distress syndrome, but in other pathologic conditions as well, where an abnormality or shortage of pulmonary surfactant may play a crucial role.
